Comparison of Genotypic (t-NGS) and Phenotypic Results for Mycobacterium tuberculosis Identification and Drug Susceptibility Testing (DST) against Tuberculosis
DOI:
https://doi.org/10.36408/mhjcm.v12i3.1256Keywords:
genotypic, Mycobacterium tuberculosis, phenotypic, sequencing, t-NGSAbstract
BACKGROUND: Accurate identification and drug susceptibility testing are crucial for tuberculosis eradication and treatment, but conventional methods require over four weeks to complete. Targeted Next Generation Sequencing (t-NGS) is a promising alternative that provides results in just four days, potentially replacing traditional methods. However, the concordance between genotypic and phenotypic methods has not been widely reported.
AIMS: This study aims to see the concordance between phenotypic and genotypic methods for identifying Mycobacterium tuberculosis and determining drug susceptibility.
METHOD: Sputum samples were collected from Balai Besar Laboratorium Kesehatan Masyarakat (BBLKM) Makassar from June 2024 until July 2024. M. tuberculosis DNA was extracted using the Qiagen DNA mini kit, amplified with Deeplex® Myc-TB by Genoscreen, and prepared with Illumina DNA Prep. t-NGS was performed on the MiSeq Illumina platform, and sequencing results were analyzed with Deeplex® Myc-TB by Genoscreen. A comparison of genotypic and phenotypic results (Culture and Drug Sensitivity Test) was conducted using SPSS.
RESULT: Discrepancies were noted between phenotypic and genotypic results for two samples (Samples 16 and 18), where phenotypic results indicated non-tuberculous mycobacteria (NTM) and genotypic results identified M. tuberculosis. These discrepancies were not statistically significant (p>0,05). Additionally, a minor discrepancy was observed in isoniazid results for one sample (Sample 2), but the statistical result is not significance (p>0.05).
CONCLUSION: t-NGS is a promising alternative to conventional methods due to its shorter testing time and capability to identify novel mutations, with discrepancies compared to phenotypic results being statistically insignificant. However, its higher cost and the need for specialized expertise limit its accessibility to some laboratories.
Downloads
References
1. Yusoof KA, García JI, Schami A, et al. Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review. Front Immunol 2022; 13: 870768.
2. WHO. Global tuberculosis report 2021.
3. Beviere M, Reissier S, Penven M, et al. The Role of Next-Generation Sequencing (NGS) in the Management of Tuberculosis: Practical Review for Implementation in Routine. Pathogens 2023; 12: 978.
4. WHO. Tuberculosis. Worid Health Organization, https://www.who.int/health-topics/tuberculosis#tab=tab_1.
5. TBC Indonesia. Ayo Bersama Akhiri TBC, Indonesia Bisa! Semangat Eliminasi TBC di Hari TBC Sedunia 2023, https://tbindonesia.or.id/ayo-bersama-akhiri-tbc-indonesia-bisa-semangat-eliminasi-tbc-di-hari-tbc-sedunia-2023/ (2023).
6. Kambli P, Ajbani K, Kazi M, et al. Targeted next generation sequencing directly from sputum for comprehensive genetic information on drug resistant Mycobacterium tuberculosis. Tuberculosis 2021; 127: 102051.
7. Murphy SG, Smith C, Lapierre P, et al. Direct detection of drug-resistant Mycobacterium tuberculosis using targeted next generation sequencing. Front Public Health 2023; 11: 1206056.
8. Cao X-J, Li Y-P, Wang J-Y, et al. MPT64 assays for the rapid detection of Mycobacterium tuberculosis. BMC Infectious Diseases 2021; 21: 336.
9. Grønningen E, Nanyaro M, Sviland L, et al. MPT64 antigen detection test improves diagnosis of pediatric extrapulmonary tuberculosis in Mbeya, Tanzania. Sci Rep 2021; 11: 17540.
10. Test MR. NILAI DIAGNOSTIK Rapid Test TbAg DAN MPT64 DENGAN KULTUR SEBAGAI GOLD STANDARD.
11. Orikiriza P, Nyehangane D, Atwine D, et al. Evaluation of the SD Bioline TB Ag MPT64 test for identification of Mycobacterium tuberculosis complex from liquid cultures in Southwestern Uganda. Afr J Lab Med 2017; 6: 383.
12. Abott. SD-Bioline-TB-Ag-MPT64.
13. Sari S, Aryati A. NILAI DIAGNOSTIK ANTIGEN TB DENGAN RAPID TEST DEVICE (TB AG) UNTUK TUBERKULOSIS PARU. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 2016; 18: 161.
14. Zhang H, Dai X, Hu P, et al. Comparison of targeted next-generation sequencing and the Xpert MTB/RIF assay for detection of Mycobacterium tuberculosis in clinical isolates and sputum specimens. Microbiol Spectr; 12: e04098-23.
15. Genoscreen. Deeplex Myc-TB Developed by Genoscreen. DeeplexMyc-Tb, https://euc1.platform.illumina.com/Deeplex/#!login (accessed 25 August 2024).
16. Walker T, Miotto P, Köser C, et al. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis. The Lancet Microbe; 3. Epub ahead of print 1 March 2022. DOI: 10.1016/S2666-5247(21)00301-3.
17. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, https://www.who.int/publications/i/item/9789240028173 (accessed 25 August 2024).
18. KEMENTERIAN KESEHATAN RI. BUKU PEGANGAN OPERASIONAL: PADUAN PENGOBATAN TBC RESISTAN OBAT DENGAN PADUAN BPAL/M. 2023rd edn. KEMENKES RI.
19. Günther G, Guglielmetti L, Kherabi Y, et al. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe. Clinical Microbiology and Infection 2024; 30: 1197.e1-1197.e4.
20. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update, https://www.who.int/publications/i/item/9789240063129 (accessed 25 August 2024).
21. Schwab TC, Perrig L, Göller PC, et al. Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: systematic review and test accuracy meta-analysis. Lancet Infect Dis 2024; 24: 1162–1176.
22. Uddin MKM, Cabibbe AM, Nasrin R, et al. Targeted next-generation sequencing of Mycobacterium tuberculosis from patient samples: lessons learned from high drug-resistant burden clinical settings in Bangladesh. Emerging Microbes & Infections 2024; 13: 2392656.
23. Ghodousi A, Tagliani E, Karunaratne E, et al. Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms. Antimicrobial Agents and Chemotherapy 2019; 63: 10.1128/aac.00092-19.
24. Abraham AO, Nasiru AU, Abdulazeez AK, et al. Mechanism of Drug Resistance in Mycobacterium Tuberculosis. AJBSR 2020; 7: 378.
25. Li G, Zhang J, Guo Q, et al. Efflux pump gene expression in multidrug-resistant Mycobacterium tuberculosis clinical isolates. PloS one 2015; 10: e0119013.
26. Jaiswal I, Jain A, Verma SK, et al. Effect of efflux pump inhibitors on the susceptibility of Mycobacterium tuberculosis to isoniazid. Lung India 2017; 34: 499–505.
27. Iyer A, Ndlovu Z, Sharma J, et al. Operationalising targeted next-generation sequencing for routine diagnosis of drug-resistant TB. Public Health Action 2023; 13: 43–49.
28. Cabibbe AM, Spitaleri A, Battaglia S, et al. Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples. Journal of Clinical Microbiology 2020; 58: 10.1128/jcm.00632-20.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2025 Paulina Rosa Evriarti, Yoeke Dewi Rasita, Harlindah Margawati, Sitti Fatimah Azzahra (Author)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
